Spasticity is among the most painful, damaging and debilitating symptoms of MS. Spasticity is characterized by sudden and uncontrollable movements of limb and torso musculature. Current drug treatments have a high level of undesirable side effects, and many patients are treated with palliative measures alone, such as pads or slings, or confined to a wheelchair.

The company's lead compound VSN16R, discovered in the labs of its scientific founders, is a novel orally active small molecule compound that does not cause the sedation or other side-effects that are major disadvantages of other agents.

Canbex is building on years of work by pioneering scientists and leading clinicians, who set out to address a medical need that is poorly served by existing therapies.